Cambridge Investment Research Advisors’s Castle Biosciences CSTL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,102	Closed	-$243K	–	3532
2024 Q4	$243K	Hold	9,102	–	–	﹤0.01%	3015
2024 Q3	$260K	Buy	+9,102	New	+$232K	﹤0.01%	2935
2023 Q1	–	Sell	-12,501	Closed	-$294K	–	3173
2022 Q4	$294K	Sell	12,501 -501	-4%	-$11.6K	﹤0.01%	2448
2022 Q3	$339K	Hold	13,002	–	–	﹤0.01%	2265
2022 Q2	$285K	Buy	13,002 +36	+0.3%	+$837	﹤0.01%	2426
2022 Q1	$582K	Buy	12,966 +1,801	+16%	+$74.4K	﹤0.01%	1985
2021 Q4	$479K	Buy	11,165 +110	+1%	+$5.75K	﹤0.01%	2137
2021 Q3	$735K	Sell	11,055 -115	-1%	-$8.09K	﹤0.01%	1765
2021 Q2	$819K	Buy	11,170 +3,394	+44%	+$224K	﹤0.01%	1688
2021 Q1	$532K	Buy	7,776 +831	+12%	+$62.5K	﹤0.01%	1862
2020 Q4	$466K	Buy	6,945 +178	+3%	+$9.65K	﹤0.01%	1815
2020 Q3	$348K	Buy	+6,767	New	+$301K	﹤0.01%	1835

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cambridge Investment Research Advisors's CSTL Position: Q1 2025 in Review

Cambridge Investment Research Advisors sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 9,102 shares — an estimated $243K sold.

Cambridge Investment Research Advisors first reported a position in CSTL in Q3 2020 and held it in 12 quarters. The position peaked at $819K in Q2 2021. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

Cambridge Investment Research Advisors reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 9,102 Castle Biosciences shares in Q1 2025, an estimated $243K.
Cambridge Investment Research Advisors first reported a position in Castle Biosciences in Q3 2020 and held it in 12 quarters.
Cambridge Investment Research Advisors's Castle Biosciences position peaked at $819K in Q2 2021.
180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.